RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis

Bomi Lee,1 Urszula T. Iwaniec,2 Russell T. Turner,2 Yi-Wei Lin,1 Bart L. Clarke,3 Anne Gingery,4 and Li-Na Wei1

1Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, USA. 2Skeletal Biology Laboratory, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, Oregon, USA. 3Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. 4Division of Orthopedic Research, Mayo Clinic, Rochester, Minnesota, USA.

Introduction

Osteoporosis is a major health concern and is characterized by loss of bone mineral density and bone quality. Osteoporosis has been reported to affect an estimated 10 million Americans over 50 years old and results in 1.5 million fragility fractures each year (1). Bone homeostasis requires a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage–specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.

Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage–specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.

Conflict of interest: The authors have declared that no conflict of interest exists.

Submitted: September 6, 2016
Accepted: February 16, 2017
Published: April 6, 2017

Reference information:

https://doi.org/10.1172/jci.insight.90517

Downloaded from http://insight.jci.org on November 6, 2017.
to question (11, 12). As recently reviewed, the beneficial skeletal effects of increased weight can be negated by metabolic dysfunction (13). For instance, women with type 2 diabetes mellitus (T2DM) have a normal or higher bone mineral density; however, they have nearly double the risk of fracture, indicating that overall quality of the bone is reduced (14). We have previously shown that the coregulator, receptor-interacting protein 140 (RIP140), plays an important role in macrophage polarization. RIP140 is a coactivator for NF-xB in proinflammatory (M1) macrophages and its degradation mediates resolution of inflammation (15). RIP140 is also a cytosolic repressor of alternative, antiinflammatory (M2) polarized macrophages (16). In mice, lowering macrophage-specific RIP140 expression levels reduces M1 macrophages, increases M2 macrophages, prevents high-fat diet–induced insulin resistance, and enhances insulin sensitivity and white adipose tissue browning even under a high-fat diet (17).

Osteoclasts are derived from the fusion of monocytes/macrophages (18). Given the prominent activities of RIP140 in the monocyte/macrophage lineage, we speculated a potential function of RIP140 in osteoclastogenesis. Macrophage colony–stimulating factor (M-CSF) activation of the M-CSF receptor/colony stimulating factor (c-Fms) and receptor activator of NF-xB ligand (RANKL) activation of its receptor RANK are important signaling events that trigger osteoclast precursor proliferation and differentiation (19, 20). RANKL signaling activates transcription factors, such as nuclear factor of activated T cells cytoplasmic 1 (NFATc1) and c-Fos, to upregulate osteoclast functional genes such as tartrate-resistant acid phosphatase (TRAP, Acp5) and cathepsin K (Ctsk) (21).

Our in vivo data indicate that RIP140 expression in osteoclasts plays a role in osteoclast differentiation, activity, and bone turnover. Here we present evidence for a physiological role of RIP140 in osteoclast precursors by regulating osteoclast differentiation through the formation of a suppressive transcription regulatory complex with testicular receptor 4 (TR4). We also show that degradation of RIP140 is key to osteoclastogenesis and bone homeostasis, and suggest a potential novel therapeutic strategy by targeting RIP140 protein in the treatment of osteolytic bone diseases.

**Results**

*Loss of osteoclast precursor RIP140 in vivo results in decreased cancellous volume.* Given RIP140's early expression and biological activity in the monocyte-macrophase lineage, and that osteoclasts differentiate from monocytes/macrophages, we speculated a functional role for RIP140 in osteoclast biology. To determine the functional relevance of RIP140 in osteoclast-associated bone homeostasis in animals, we carefully examined the bone phenotype of a monocyte/macrophage–specific RIP140-knockdown transgenic mouse model, mRIP140KD. As described in our previous study (15), endogenous microRNA was used to mimic RIP140-specific shRNA driven by the human CD68 promoter in mRIP140KD mice. In vitro osteoclast differentiation was first carried out using bone-marrow cells from tibias and femurs of WT and mRIP140KD mice, and cells were induced with RANKL and M-CSF for 2 days. The expression of osteoclast marker genes Nfatc1, Ctsk, and Acp5 in mRIP140KD cultures was significantly elevated following RANKL treatment as compared with WT (Supplemental Figure 1A; supplemental material available online with this article: https://doi.org/10.1172/jci.insight.90517DS1), suggesting a suppressive role for RIP140 in osteoclastogenesis. RIP140 KD efficiency was confirmed (Supplemental Figure 1A).

To further validate mRIP140KD in suppressing osteoclastogenesis in vivo, we performed micro-computed tomography (μCT) and histomorphometric analysis of WT and mRIP140KD bones. A representative μCT image (Figure 1A) of the femoral diaphysis and metaphysis shows cortical and cancellous bone volume fraction in control and mRIP140KD mice. Significant differences in cortical bone parameters in the femur diaphysis were not detected with genotype (Figure 1B). Additionally, reference point indentation material properties assessed ex vivo on the tibia of control and mRIP140KD mice were not significantly different (Supplemental Figure 1B). In contrast, bone volume fraction (calculated as percentage bone volume/tissue volume [BV/TV]) at both the distal femur metaphysis (47%) and the fifth lumbar vertebra (L5, 18%) was significantly lower in mRIP140KD mice compared with WT mice (Figure 1, C and D). Significant reductions in cancellous bone volume fraction in the femur metaphysis were associated with a significant reduction in connectivity density and trabecular number and thickness (Figure 1C). There were no significant differences in trabecular spacing, though it approached significance (P = 0.059) (Figure 1C). For L5, the bone volume fraction and trabecular thickness were also significantly reduced and trabecular spacing was significantly increased in vertebrae in mRIP140KD mice (Figure 1D). These μCT and histomorphometric analyses revealed that mRIP140KD mice have an osteopenic phenotype with decreased cancellous bone volume.
Loss of mϕRIP140 in osteoclast precursors results in increased osteoclast activity, reduced osteoblast activity, and reduced bone formation. Bone turnover involves coupling of osteoblast-mediated bone formation to osteoclast-mediated bone resorption. To examine the effect of reducing RIP140 on the osteoclast-osteoblast coupling, we assessed bone resorption and formation indices in mϕRIP140KD mice. The effects of geno-
Type on bone formation (incorporation of label into mineralizing bone) and bone resorption (osteoclast perimeter) can be appreciated in Figure 2A. Mineralizing perimeter, bone formation rate, and mineral apposition rate were significantly reduced (−50%, −59%, and −19%, respectively) in the femur metaphysis of \( \psi \)RIP140KD mice as compared with WT (Figure 2B). Osteoblast perimeter/bone perimeter was significantly decreased (−60%) with a concomitant increase (+51%) in osteoclast perimeter/bone perimeter in \( \psi \)RIP140KD mice, indicating uncoupling of osteoclast and osteoblast formation (Figure 2B). Furthermore, TRAP activity, a mature osteoclast functional indicator, was increased, whereas osteoblast alkaline phosphatase was significantly reduced (Figure 2C), further confirming that the coupling has been affected by reducing RIP140 expression to enhance osteoclastogenesis.

To further confirm the effect of RIP140 KD in osteoclast differentiation in vitro, we employed osteoclast differentiation assay with bone marrow cells from WT and \( \psi \)RIP140KD mice (22). After 5 days incubation...
with M-CSF and RANKL, osteoclasts were significantly increased in cultures from mϕRIP140KD mice (Figure 3A), indicating an increase in osteoclast differentiation when RIP140 levels are low.

Conditioned medium (CM) from osteoclast cultures derived from WT or mϕRIP140KD bone marrow was used in osteoblasts derived from long bones (Figure 3B) and MC3T3-E1 osteoblasts (Supplemental Figure 2A) to assess in vitro coupling of osteoclasts to bone formation responses. Markers of osteoblast differentiation Runx2, Sp7 (osterix), and Alpl (alkaline phosphatase) were assessed by quantitative reverse transcription PCR (qRT-PCR). Consistent with the result of osteoblast activity in mouse serum, osteoblast marker gene expression was substantially diminished by treatment with CM of osteoclasts derived from mϕRIP140KD mice (Figure 3B and Supplemental Figure 2A). Additionally, gene expression analysis of osteoclast cultures showed significant regulation of multiple known osteoclast coupling factors (Supplemental Figure 2B) including a significant reduction of the recently identified osteoclast coupling factor Wnt1 (22). These data further support the functional consequence of depleting RIP140 in osteoclasts in vivo; depleting RIP140 enhances osteoclast differentiation and activity, and decreases in vivo osteoblast differentiation, indicating an uncoupling of osteoclasts and osteoblasts.

TR4/RIP140 complex formation and repression of osteoclast gene expression. To examine the underlying mechanism of mϕRIP140’s suppressive activity in osteoclast differentiation and activity, we first sought to identify the RIP140 complex involved in early phases of osteoclast differentiation by examining RIP140-containing complexes in the murine preosteoclast cell line RAW264.7 (23). We introduced a FLAG-RIP140 vector into RAW264.7 cells and immunoprecipitated nuclear FLAG-RIP140 complexes. Mass spectrometry data revealed TR4 (Nr2c2), a previously reported nuclear receptor that acts primarily to repress genes (24, 25), with the greatest number of unique reads (Figure 4A). TR4/RIP140 complex formation was confirmed by coimmunoprecipitation assays in RAW264.7 cells (Figure 4B) and in 293T cells (Figure 4C). Interestingly, TR4 mRNA and protein expression was downregulated following RANKL treatment (Figure 4D).

We then performed TR4 KD in RAW264.7 cells under RANKL stimulation and found elevated expression of Nfatc1, Csk, and Acp5, markers of osteoclast differentiation (Figure 4E). In contrast, overexpression of TR4 in RANKL-stimulated RAW264.7 cells rendered significant or nearly significant downregulation of osteoclast genes (Supplemental Figure 3A), which further supports a repressive activity of the TR4 complex in osteoclast differentiation (see below for the corepressive activity of RIP140). We validated TR4 binding to endogenous osteoclast marker gene promoters. This binding was reduced by RANKL treatment,
which was recovered by replenishing RIP140 with doxycycline-induced RIP140 overexpression (Figure 4F). Taken together, these data reveal that RIP140 forms a complex with TR4 in preosteoclastic cells to suppress osteoclast differentiation by directly targeting promoter regions of genes critical for osteoclast differentiation or activity. As cells are stimulated with RANKL for osteoclast differentiation, the protein level of the TR4/RIP140 complex is downregulated, allowing differentiation to proceed.

**RIP140’s repressive activity and protein degradation in RANKL-stimulated osteoclast differentiation.** To further confirm the repressive role of RIP140 in osteoclast differentiation, we performed a gain-of-function study in RANKL-stimulated RAW264.7 cells. Elevating RIP140 levels dampened the expression of differentiation markers (Figure 5A), confirming the repressive activity of RIP140 in RANKL-induced osteoclast differentiation. Interestingly, RANKL stimulation decreased RIP140 protein levels without altering RIP140 mRNA expression (Figure 5, B and C), suggesting posttranslational regulation to lower RIP140 protein levels by RANKL stimulation. We previously identified Syk, a nonreceptor tyrosine kinase that stimulated a RIP140 protein ubiquitination/degradation pathway in M1-polarized macrophages (15). Interestingly, Syk inhibition reduced RANKL-induced RIP140 protein degradation and osteoclast gene expression (Figure 5, B and D). Syk has been previously noted to be an important kinase involved in mature osteoclast cytoskeletal organization (26). Our data imply that Syk may have an additional role: to stimulate RIP140 degradation during osteoclast differentiation, leading to enhanced osteoclast differentiation. To provide further evidence for the significance of RIP140 degradation in this process, lentiviruses carrying either WT or a nondegradable RIP140 mutant (Y3F) were introduced into bone marrow–derived mononuclear cells, which were then treated with M-CSF and RANKL for osteoclast differentiation. As predicted, differentiation markers were dampened by expressing WT RIP140, and completely blocked by expressing Y3F that could not be degraded (Figure 5E). Thus, RIP140 exerts a repressive activity for RANKL-stimulated osteoclast differentiation, and is degraded over time by RANKL treatment, allowing differentiation to proceed. Additionally, we conclude that the TR4/RIP140 complex is a suppressor of osteoclast differentiation genes. RANKL signal triggers RIP140 protein degradation and TR4 mRNA downregulation, providing a physiological break to terminate the potent suppressive activity of RIP140 in osteoclast differentiation.

**RIP140 suppresses RANKL signaling.** RANKL signaling is known to activate NF-xB and MAPK to induce osteoclast differentiation (27–29). To determine if RIP140 regulates endogenous signaling components, we overexpressed RIP140 in RAW264.7 cells overnight, induced cells with RANKL, and monitored the activation of endogenous signaling components following RANKL treatment. As shown in Figure 6A, RANKL induced MEK1/2, ERK1/2, and p65 phosphorylation within 30 minutes in control cells, which was reduced by overexpressing RIP140 in RAW264.7 cells, indicating that RIP140 interfered with activation of endogenous signaling. Furthermore, we noted that RANKL-induced TRAP was dose-dependently reduced by overexpressing RIP140 (Figure 6B). Since RIP140 can regulate gene expression by interacting with transcription regulators, we explored whether RIP140 could also act as a transcription coregulator of upstream signaling molecules RANK or TNF receptor–associated factor (TRAF). In chromatin immunoprecipitation (ChIP) assay, RIP140 was not detected on RANK or TRAF promoters, ruling out RIP140 being directly involved in RANKL-dependent NF-xB and MAPK activation at the transcription level. However, RIP140 was detected on the Nfatc1 promoter (Figure 6C), which was reduced upon RANKL stimulation. TR4 binding to Nfatc1 was significantly enhanced by overexpressing RIP140 in unstimulated cells. In the later (24 hours) phase of RANKL stimulation, TR4 was no longer detected on this gene (Figure 6C). In unstimulated cells, the Nfatc1 promoter was bound by the major activating transcription factors, NFATc1 itself and PU.1, which was enhanced by RANKL treatment. But overexpressing RIP140 reduced binding of these activating transcription factors (Figure 6C), indicating that RIP140 plays a negative role in transcriptional regulation of the osteoclastogenic program. Consistently, RANKL-triggered transcription activation marks such as H3 acetylation were dampened and transcription silencing markers such as H3K9 trimethylation were enhanced by increasing RIP140 expression (Figure 6C). Together, these data show a negative role for RIP140 in regulation of the osteoclastogenic program.

**Discussion**

In this study, we report the m4RIP140KD mouse model, which exhibits a cancellous osteopenic phenotype with increased osteoclast-lined and reduced osteoblast-lined bone perimeter, ultimately resulting in decreased bone formation rate and cancellous bone volume, similar to what is seen in some forms of osteoporosis (e.g., glucocorticoid-induced osteoporosis) (30). Significant declines in cancellous bone
Figure 4. TR4/RIP140 complex formation and repressive activity in osteoclast differentiation. (A) Silver staining of FLAG-RIP140–associated proteins in RAW264.7 cells. (B) Western blot analysis of RIP140/TR4 complex in RAW264.7 cells. (C) Coimmunoprecipitation (IP) of FLAG-RIP140/HA-TR4 from HEK293T. (D) qRT-PCR and Western analyses of TR4 after RANKL stimulation for 2 days. (E) qRT-PCR analysis of osteoclast marker genes in control (GFP KD) versus TR4-knockdown (TR4 KD) RAW264.7 cells with or without RANKL treatment for 24 hours. Additional statistical significance shown in E was determined by 2-way ANOVA. (F) ChIP assay of TR4 on osteoclast marker gene promoters in RAW264.7 cells treated with RANKL stimulation for 30 minutes. RIP140 overexpression was induced by doxycycline pretreatment (250 ng/ml) for 6 hours. Additional statistical significance was determined by 1-way ANOVA (Nfatc1 promoter $P = 0.0014$, Ctsk promoter $P < 0.0001$, Acp5 promoter $P < 0.0001$). Data are representative of 3 experimental repeats (mean ± SD). For all graphs, Student’s t test ($n = 3$) was used unless otherwise specified. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. 
Figure 5. RIP140 represses osteoclast differentiation and is degraded by RANKL treatment in osteoclast differentiation. (A) qRT-PCR analyses of osteoclast markers in control (FLAG) or FLAG-RIP140-overexpressing RAW264.7 cells treated with RANKL for 2 days. (B) Western blot analyses of RIP140 in RAW264.7 cells treated with RANKL for indicated time periods with or without Syk (nonreceptor tyrosine kinase) inhibitor pretreatment. (C) qRT-PCR analyses of RIP140 in RAW264.7 cells with or without RANKL treatment for 4 days. NS, not significant. (D) qRT-PCR analyses of osteoclast markers in RAW264.7 cells treated with RANKL for 2 days with or without Syk inhibitor pretreatment. (E) qRT-PCR analyses. Bone marrow-derived osteoclasts were differentiated with M-CSF and RANKL (RK-M-CSF) for 3 days following transduction with lentiviruses carrying control (Ctrl), WT RIP140, or nondegradable mutant RIP140 (Y3F). Data are representative of 3 experimental repeats (mean ± SD). For all graphs, Student’s t test (n = 3) was used unless otherwise specified. *P < 0.05, **P < 0.01, ***P < 0.001. Additional statistical significance shown in A, D, and E was determined by 2-way ANOVA.
Volume fraction were seen in distal femur metaphysis and lumbar vertebra. The observed deficits in RIP140 KD bone were limited to cancellous compartments, an observation consistent with the proposed mechanism of action. Cancellous bone balance is primarily determined by coupled bone turnover. While cortical bone in humans undergoes lifelong bone remodeling, this is not the case in mice; cortical bone mass in small rodents is primarily determined by longitudinal and radial growth (31). RIP140 in macrophage–derived osteoclast precursors acts as a negative regulator of osteoclast differentiation. In WT animals, RANKL treatment attenuates RIP140 action as a result of a reduction in RIP140 protein, and its transcriptional complex partner TR4 mRNA, providing a physiological brake to terminate this critical gatekeeper of osteoclastogenesis. Additionally, the RIP140/TR4 complex targets key genes involved in osteoclast differentiation and activity including Nfatc1, Csk, and Acp5.

Figure 6. RIP140 suppresses RANKL signaling and transcription activation of osteoclastogenic genes. (A) Western blot analyses of Flag-HA-RIP140 and MAPK/NF-κB signaling components in whole-cell lysates from control versus RIP140-overexpressing RAW264.7 cells. RIP140 overexpression was induced by doxycycline for 16 hours and cells were treated with RANKL at indicated times. (B) Tartrate-resistant acid phosphatase (TRAP) activity in doxycycline-induced (Dox) RIP140-expressing RAW264.7 cells. Statistical significance was determined with Student’s t test (n = 3), and each treated sample was compared to unstimulated one. (C) ChIP assay of HA-RIP140, TR4, NFATc1, PU.1, H3Ac, and H3K9me3 on the Nfatc1 promoter in doxycycline-induced RIP140-expressing RAW264.7 cells after RANKL treatment (0.5 hours for H3Ac and H3K9me3, 6–24 hours for others). Additional statistical significance in C was determined by 2-way ANOVA. Data are representative of 3 experimental repeats (mean ± SD). For all graphs, Student’s t test (n = 3) was used unless otherwise specified. *P < 0.05, **P < 0.01, ***P < 0.001.
Consistent with in vivo studies, primary osteoblasts and osteoblastic MC-3T3 cells cultured with CM from m\(\text{RIP140KD}\) primary osteoclasts had significantly reduced osteoblast marker gene expression. This indicates that RIP140 in osteoclasts is also an important regulator of osteoclast-mediated cross-talk with osteoblasts. Further, transcriptional regulation of osteoclast-derived coupling factors was dysregulated. While some known coupling factors (\(\text{Sphk1, Pdgfb, Cthrc1, and Bmp5}\)) were not substantially changed, multiple coupling factors were significantly increased, including \(\text{Bmp6, Wnt10b, and Ctgf}\) in m\(\text{RIP140KD}\) osteoclasts compared with WT. This may be a compensatory response to the uncoupling between osteoclasts and osteoblasts. Interestingly, we found that \(\text{Wnt1}\) was significantly downregulated in RIP140-ablated osteoclasts. Recent work has shown that \(\text{Wnt1}\) is an important osteoclast-derived coupling factor and disruption of this factor results in an uncoupling of osteoclasts-osteoblasts (22).

Here we note that MEK, ERK, and NF-κB signaling was inhibited by RIP140 overexpression, indicating that RIP140 acts, at least in part, to inhibit second messenger activation. Interestingly, and in contrast to our finding in inflammatory macrophages where RIP140 is associated with the NF-κB subunit RelA protein, immunoprecipitation assays with RIP140 and RelA performed here show no interaction in osteoclasts. Further mass spectrometry analysis did not identify RelA as a RIP140KD-interacting protein in preosteoclasts. While RIP140 may regulate second messenger signaling, we also saw that RIP140 is strongly associated with TR4 in osteoclasts as a transcriptional regulatory complex to regulate important osteoclast target gene promoters. This further supports the notion that RIP140 may regulate osteoclast differentiation at both the protein and at the transcriptional level. The anti-osteoclastogenesis potential of the RIP140/TR4 complex is also supported by whole-body TR4 knockout, which leads to postnatal mortality and growth retardation, impaired reproduction and maternal behavior in female mice (32), and impaired skeletal development including osteoporosis with reduced osteoblast activity (33).

Of further significance is the rapid degradation of RIP140 protein upon RANKL treatment mediated by, at least in part, Syk-mediated phosphorylation. This is distinct from the corepressor factor, TR4, whose expression is reduced primarily at the level of mRNA. This suggests a potential new therapeutic strategy for managing bone diseases by blocking osteoclast RIP140 protein degradation to attenuate osteoclastogenesis. It is important to note that previous work on Syk inhibition have found that Syk arrests terminal events of osteoclastogenesis; however, this does not impact the regulation of \(\text{Nfkb1}\) at early time points (34). Recent work has shown that Syk activation is important for organization of the mature osteoclast cytoskeleton and subsequent osteoclast activity (26). Additionally, it has been reported that Syk-deficient bone marrow macrophages do not have a delay in differentiation (35). Our findings concerning the protein regulation of RIP140 have uncovered a potentially novel and previously unknown role for Syk in osteoclast differentiation, namely the regulation of RIP140.

Several reports have indicated RIP140 as a candidate gene associated with bone-related traits and osteoporosis in microarray, multilocus single nucleotide polymorphisms (SNPs) analysis (36). Further evidence has shown that RIP140 gene expression in hematopoietic cells is correlated with bone mineral density (37). Additionally, studies of Spanish postmenopausal women detected genetic interactions between RIP140 and other estrogen-related genes such as \(\text{ESR2}\) and \(\text{BMP15}\) loci, and the involvement of RIP140 in osteoporosis (38). A previous report suggested that a correlation between estrogen signaling in mature osteoclasts may act through RIP140; however, this report provided no direct evidence of an estrogen receptor/RIP140 complex, focused on mature osteoclasts, and used a nonphysiologic model of estrogen withdrawal in both reproductive and skeletally immature animals (39). A recent report also showed cancellous changes in a global knockout model of RIP140; however, given RIP140’s known systemic effects, a direct correlation to osteoclast activity is unclear (40). Given RIP140’s wide-spectrum activities, such as in metabolism and inflammation, nondiscriminatingly targeting RIP140 might negate the beneficial impact of RIP140 ablation in osteoclast macrophage precursors (15–17).

Importantly, our results have provided unambiguous evidence for RIP140 and the RIP140/TR4 transcription complex playing a role in osteoclastogenesis, and conclude that RIP140 plays a crucial role in maintaining bone health. Increased osteoclast number and bone resorption are characteristic of bone destructive diseases such as osteoporosis, osteolytic bone metastases, and rheumatoid arthritis. Therefore, an important therapeutic strategy for these diseases is to maintain the coupled resorption and formation that is found in healthy bone turnover. Specifically targeted therapeutics that can regulate osteoclast activity and cross-talk with osteoblast activity would be an important leap forward in therapeutic design, rather than relying on substantial inhibition of osteoclast activity or survival. The potential to target osteoclast-specific RIP140
protein degradation to attenuate osteoclastogenesis and activity is an intriguing strategy. Further studies to investigate the regulation of RIP140 in both signal regulation and transcriptional regulation are warranted.

In summary, our results reveal a potentially novel role for RIP140 in osteoclast differentiation, activity, and bone turnover.

Methods

Reagents and procedures for cell cultures, mass spectrometry, and immunoprecipitation are described in the supplemental data.

Animals. All studies were carried out using male C57BL/6J mice maintained in the animal facility of the University of Minnesota. Nine-week-old male mice (n = 8–10/group) were injected with the fluoro-chrome calcein (12.5 mg/kg; Sigma-Aldrich) 4 days and 1 day prior to sacrifice to label mineralizing bone. mØRIP140KD mice were generated as described (15). To generate transgenic mice overexpressing shRNA targeting RIP140 in a monocyte/macrophage lineage, endogenous microRNA was used to mimic RIP140-specific shRNA (41) and the expression was driven by the human CD68 promoter (42). The DNA fragment was subcloned into the pWhere vector, and the transgenic DNA was excised and injected into C57BL/6 mouse oocytes (Mouse Genetics Laboratory, University of Minnesota). Transgenic founder mice were genotyped by PCR using the following primers: forward, 5′-GAGTTTCAGACGCTTGAAAGCC-3′ and reverse, 5′-GTCAATTATGTCACACCAGAAG-3′.

μCT. μCT was used for nondestructive 3-dimensional evaluation of bone volume and architecture as described (43). Details are provided in supplemental methods.

Histomorphometry. Methods used for measuring static and dynamic bone histomorphometry have been described (44). Details are provided in supplemental methods.

Immunoprecipitation and mass spectrometry. FLAG-RIP140 RAW264.7 cells were treated with or without doxycycline (250 ng/ml) for 6 hours. Cells were washed with PBS and harvested. Nuclear extracts were prepared using hypotonic buffer, low-salt buffer, and high-salt buffer. Nuclear extracts were treated with Benzonase nuclease (Sigma-Aldrich) and then dialyzed in BC300 (45). After preclearing with mouse IgG-agarose beads, nuclear extracts were immunoprecipitated with anti-FLAG M2 magnetic beads (Sigma-Aldrich) and washed with 0.1% NP-40–containing BC300. FLAG-RIP140–bound proteins were eluted with FLAG peptides (Sigma-Aldrich), and samples were sent to the Taplin Biological Mass Spectrometry Facility at Harvard Medical School for mass spectrometry analysis. FLAG-RIP140–binding proteins were validated with Western blot analysis using specific antibodies.

Cell culture, TRAP staining, and CM experiments. RAW264.7 (TIB-71) and MC3T3-E1 (CRL-2593) cells were purchased from ATCC. Bone marrow cells were isolated from mouse femurs and tibias by flushing bone marrow with PBS. After lysing red blood cells, bone marrow cells were plated (4 × 10^5 cells/well) in 24-well plates and incubated with differentiation media (α-MEM medium supplemented with 10% FBS, 1% antibiotics, RANKL [100 ng/ml], and M-CSF [25 ng/ml]) for 4 days. On day 5, cells were fixed with 4% paraformaldehyde and stained for TRAP (Sigma-Aldrich) as previously reported (27). For the CM, FBS-containing fresh α-MEM medium was added to primary osteoclasts differentiated with M-CSF and RANKL for 5 days. After a 24-hour incubation, CM was collected and added to MC3T3-E1 cells or primary osteoblasts for 3 days with ascorbic acid (50 μg/ml) for osteoblast differentiation.

DNA constructs, lentivirus production, and transduction. WT-RIP140 and Y3F-RIP140 expression lentivirus constructs were prepared as described (15). The doxycycline-inducible FLAG-HA-RIP140 expression lentivirus construct was made as described (46). Viruses were generated by transfection of lentivirus constructs and packaging plasmids in HEK293T cells. The culture medium including viruses was harvested 2–3 days after transfection, and filtered to remove nonadherent 293T cells. Filtered viruses were concentrated with Lenti-X (Clontech, 631232) overnight. Viruses were collected by centrifugation and saved at −80°C. For virus transduction in cells, viruses were incubated in Polybrene-containing (EMD Millipore) media for 3 days.

Statistics. In vitro experiments were performed at least 3 times. In vivo experiments (n = 810) are reported. Results are presented as box-and-whisker plots, with the center line representing the median. The whiskers indicate the 10th and 90th percentiles. Unpaired and 2-tailed Student’s t test was used for both in vitro (parametric) and in vivo (nonparametric) analysis. P values of 0.05 or less were considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). Two-way ANOVA was performed to examine the influence of 2 independent factors: the model and the treatment.

Study approval. All the animal studies have been approved by the University of Minnesota IACUC.
Author contributions
BL, AG, and LNW designed research. BL and AG performed research. BL, UTI, RTT, YWL, and AG collected data. BL, UTI, RTT, YWL, BLC, AG, and LNW contributed to the discussion, and reviewed and wrote the manuscript.

Acknowledgments
This work was supported by NIH grants DK54733, DK60521, and DK60521-12S1, the Dean's Commitment and the Distinguished McKnight Professorship of the University of Minnesota (to L.N.W.), and NIH grant F32-AR063596, Mayo Clinic Center for Regenerative Medicine (to A.G.).

Address correspondence to: Li-Na Wei, Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA. Phone: 612.625.9402; E-mail: weixx009@umn.edu.

28. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in termi-


